- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Retail price of 51 formulations fixed by NPPA
Overview
Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of the 51 formulations including those used to treat type 2 diabetes, bacterial infections, and others.
This came in line with the decision of the 114th Authority meeting dated 19.06.2023, where the authority discussed the new drug applications for price fixation under para 5 and 15 of DPCO 2013.
These include Skymap Healthcare & Healing Pharma's Ciprofloxacin & Dexamethasone Eye Drops, Cris Pharma& Mankind Prime Lab's Paracetamol, Phenylephrine and Chlorpheniramine Drops, Akums Drugs & Eris Life science's Paroxetine Controlled release & Clonazepam Capsules.
For more details, check out the link given below:
NPPA Fixes Retail Price Of 51 Formulations, Details